KIM LLC’s enGene Therapeutics Warrants ENGNW Stock Holding History

KIM LLC’s Portfolio ENGNW Stock Details ENGNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-33,333	Closed	-$28.3K	–	264
2023 Q4	$28.3K	Buy	+33,333	New	+$25.6K	﹤0.01%	186

Other funds holding ENGNW

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Calamos Advisors

Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Atalaya Capital Management New York $45M AUM 3.02% 1-Year Est. Return

Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return

KIM LLC's ENGNW Position: Q1 2024 in Review

KIM LLC sold out of enGene Therapeutics Warrants (ENGNW) in Q1 2024, closing a stake of 33,333 shares — an estimated $28.3K sold.

KIM LLC first reported a position in ENGNW in Q4 2023 and held it in 1 quarter. The position peaked at $28.3K in Q4 2023. 16 funds tracked by Wall St. Rank hold ENGNW as of Q1 2024.

KIM LLC reported no remaining enGene Therapeutics Warrants position as of Q1 2024 after selling out during the quarter.
KIM LLC sold 33,333 enGene Therapeutics Warrants shares in Q1 2024, an estimated $28.3K.
KIM LLC first reported a position in enGene Therapeutics Warrants in Q4 2023 and held it in 1 quarter.
KIM LLC's enGene Therapeutics Warrants position peaked at $28.3K in Q4 2023.
16 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q1 2024.

Based on KIM LLC's 13F filing for Q1 2024, filed 13 May 2024.